# Figma, Inc.: financial statements, quarterly

FIG · NYSE · CIK 1579878 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fig.md) · [Financials](/companies/fig/financials.md) · [Filings](/companies/fig/filings.md) · [Insiders](/companies/fig/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fig/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [177](/filings/0001579878-25-000027.md) | [199](/filings/0001628280-25-049683.md) | [217 d](/filings/0001628280-26-009228.md) | [228](/filings/0001628280-26-035209.md) | [250](/filings/0001628280-26-053348.md) | [274](/filings/0001628280-25-049683.md) | [304 d](/filings/0001628280-26-009228.md) | [333](/filings/0001628280-26-035209.md) | [370](/filings/0001628280-26-053348.md) |
| Cost of revenue | $m | [39.6](/filings/0001579878-25-000027.md) | [18.7](/filings/0001628280-25-049683.md) | [16.5 d](/filings/0001628280-26-009228.md) | [19.5](/filings/0001628280-26-035209.md) | [27.9](/filings/0001628280-26-053348.md) | [83.9](/filings/0001628280-25-049683.md) | [54.3 d](/filings/0001628280-26-009228.md) | [68.7](/filings/0001628280-26-035209.md) | [60.5](/filings/0001628280-26-053348.md) |
| Gross profit | $m | [138](/filings/0001579878-25-000027.md) | [180](/filings/0001628280-25-049683.md) | [200 d](/filings/0001628280-26-009228.md) | [209](/filings/0001628280-26-035209.md) | [222](/filings/0001628280-26-053348.md) | [190](/filings/0001628280-25-049683.md) | [249 d](/filings/0001628280-26-009228.md) | [265](/filings/0001628280-26-035209.md) | [310](/filings/0001628280-26-053348.md) |
| Research and development | $m | [536](/filings/0001579878-25-000027.md) | [104](/filings/0001628280-25-049683.md) | [58.6 d](/filings/0001628280-26-009228.md) | [69.9](/filings/0001628280-26-035209.md) | [83.1](/filings/0001628280-26-053348.md) | [681](/filings/0001628280-25-049683.md) | [196 d](/filings/0001628280-26-009228.md) | [173](/filings/0001628280-26-035209.md) | [167](/filings/0001628280-26-053348.md) |
| Operating income | $m | [(894)](/filings/0001579878-25-000027.md) | [(47.3)](/filings/0001628280-25-049683.md) | [51.7 d](/filings/0001628280-26-009228.md) | [39.7](/filings/0001628280-26-035209.md) | [2.1](/filings/0001628280-26-053348.md) | [(1,137)](/filings/0001628280-25-049683.md) | [(196) d](/filings/0001628280-26-009228.md) | [(137)](/filings/0001628280-26-035209.md) | [(117)](/filings/0001628280-26-053348.md) |
| Income tax | $m | [(56.3)](/filings/0001579878-25-000027.md) | [(13.8)](/filings/0001628280-25-049683.md) | [(7.0) d](/filings/0001628280-26-009228.md) | [2.1](/filings/0001628280-26-035209.md) | [10.8](/filings/0001628280-26-053348.md) | [(10.5)](/filings/0001628280-25-049683.md) | [22.3 d](/filings/0001628280-26-009228.md) | [0.7](/filings/0001628280-26-035209.md) | [2.5](/filings/0001628280-26-053348.md) |
| Net income | $m | [(828)](/filings/0001579878-25-000027.md) | [(15.6)](/filings/0001628280-25-049683.md) | [97.8 d](/filings/0001628280-26-009228.md) | [44.9](/filings/0001628280-26-035209.md) | [28.2](/filings/0001628280-26-053348.md) | [(1,097)](/filings/0001628280-25-049683.md) | [(227) d](/filings/0001628280-26-009228.md) | [(142)](/filings/0001628280-26-035209.md) | [(112)](/filings/0001628280-26-053348.md) |
| Diluted EPS | $ per share | [(4.39)](/filings/0001579878-25-000027.md) | [(0.07)](/filings/0001628280-25-049683.md) | not reported | [0.04](/filings/0001628280-26-035209.md) | [0.00](/filings/0001628280-26-053348.md) | [(2.72)](/filings/0001628280-25-049683.md) | not reported | [(0.27)](/filings/0001628280-26-035209.md) | [(0.21)](/filings/0001628280-26-053348.md) |
| Basic EPS | $ per share | [(4.39)](/filings/0001579878-25-000027.md) | [(0.07)](/filings/0001628280-25-049683.md) | not reported | [0.04](/filings/0001628280-26-035209.md) | [0.00](/filings/0001628280-26-053348.md) | [(2.72)](/filings/0001628280-25-049683.md) | not reported | [(0.27)](/filings/0001628280-26-035209.md) | [(0.21)](/filings/0001628280-26-053348.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [1,270](/filings/0001628280-26-009228.md) | not reported | [586](/filings/0001579878-25-000027.md) | [416](/filings/0001628280-25-049683.md) | [487](/filings/0001628280-26-009228.md) | [619](/filings/0001628280-26-035209.md) | [622](/filings/0001628280-26-053348.md) | [340](/filings/0001628280-25-049683.md) | [403](/filings/0001628280-26-053348.md) | [406](/filings/0001628280-26-035209.md) | [446](/filings/0001628280-26-053348.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [1,638](/filings/0001628280-26-009228.md) | not reported | [1,808](/filings/0001579878-25-000027.md) | [1,844](/filings/0001628280-25-049683.md) | [2,005](/filings/0001628280-26-053348.md) | [1,936](/filings/0001628280-26-035209.md) | [1,977](/filings/0001628280-26-053348.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [1,793](/filings/0001628280-26-009228.md) | not reported | [2,035](/filings/0001579878-25-000027.md) | [2,073](/filings/0001628280-25-049683.md) | [2,348](/filings/0001628280-26-053348.md) | [2,291](/filings/0001628280-26-035209.md) | [2,351](/filings/0001628280-26-053348.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [447](/filings/0001628280-26-009228.md) | not reported | [547](/filings/0001579878-25-000027.md) | [622](/filings/0001628280-25-049683.md) | [776](/filings/0001628280-26-053348.md) | [774](/filings/0001628280-26-035209.md) | [807](/filings/0001628280-26-053348.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [469](/filings/0001628280-26-009228.md) | not reported | [607](/filings/0001579878-25-000027.md) | [685](/filings/0001628280-25-049683.md) | [838](/filings/0001628280-26-053348.md) | [834](/filings/0001628280-26-035209.md) | [873](/filings/0001628280-26-053348.md) |
| Shareholders' equity | $m | [286](/filings/0001628280-26-009228.md) | [1,043](/filings/0001628280-26-009228.md) | [1,057](/filings/0001579878-25-000027.md) | [862](/filings/0001628280-25-049683.md) | [1,168](/filings/0001628280-25-049683.md) | [1,324](/filings/0001628280-26-053348.md) | [1,370](/filings/0001628280-26-053348.md) | [1,427](/filings/0001628280-26-053348.md) | [1,389](/filings/0001628280-25-049683.md) | [1,511](/filings/0001628280-26-053348.md) | [1,457](/filings/0001628280-26-053348.md) | [1,478](/filings/0001628280-26-053348.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [61.6 d](/filings/0001628280-25-049683.md) | [73.1 d](/filings/0001628280-26-009228.md) | [97.2](/filings/0001628280-26-035209.md) | [62.5 d](/filings/0001628280-26-053348.md) | [51.2 d](/filings/0001628280-25-049683.md) | [39.9 d](/filings/0001628280-26-009228.md) | [97.3](/filings/0001628280-26-035209.md) | [60.9 d](/filings/0001628280-26-053348.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001628280-25-049683.md) | [0.7 d](/filings/0001628280-26-009228.md) | [0.9](/filings/0001628280-26-035209.md) | [1.1 d](/filings/0001628280-26-053348.md) | [1.7 d](/filings/0001628280-25-049683.md) | [0.7 d](/filings/0001628280-26-009228.md) | [7.8](/filings/0001628280-26-035209.md) | [6.7 d](/filings/0001628280-26-053348.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-25-049683.md) | [0.0 d](/filings/0001628280-26-009228.md) | not reported | not reported | [0.0 d](/filings/0001628280-25-049683.md) | [0.0 d](/filings/0001628280-26-009228.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [189](/filings/0001579878-25-000027.md) | [211](/filings/0001628280-25-049683.md) | [231](/filings/0001628280-26-035209.md) | [232](/filings/0001628280-26-053348.md) | [403](/filings/0001628280-25-049683.md) | [523](/filings/0001628280-26-035209.md) | [527](/filings/0001628280-26-053348.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.